Fielder Capital Group’s Moderna MRNA Stock Holding History

Fielder Capital Group’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$266K	Sell	3,803 -327	-8%	-$16.9K	0.06%	238
2026 Q1	$210K	Buy	+4,130	New	+$193K	0.05%	272

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Fielder Capital Group's MRNA Position: Q2 2026 in Review

Fielder Capital Group reduced its Moderna (MRNA) stake by 7.9% in Q2 2026, selling an estimated $16.9K and leaving 3,803 shares worth $266K. The position accounts for 0.06% of the portfolio, ranked #238.

Fielder Capital Group first reported a position in MRNA in Q1 2026 and has held it in 2 quarters since. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Fielder Capital Group held 3,803 shares of Moderna worth $266K as of Q2 2026.
Fielder Capital Group sold 327 Moderna shares in Q2 2026, an estimated $16.9K.
Moderna made up 0.06% of Fielder Capital Group's portfolio in Q2 2026, its #238 holding.
Fielder Capital Group first reported a position in Moderna in Q1 2026 and has held it in 2 quarters since.
783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Fielder Capital Group's 13F filing for Q2 2026, filed 6 Aug 2026.